Related Experiment Video

Updated: Jul 3, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Cytochrome P450 and gene activation--from pharmacology to cholesterol elimination and regression of atherosclerosis

Pauli V Luoma1

  • 1Institute of Biomedicine, Pharmacology, University of Helsinki, Helsinki, Finland. eeva.harju@helsinki.fi

European Journal of Clinical Pharmacology
|July 18, 2008
PubMed

Insights

Cytochrome P450 enzymes are crucial for maintaining cholesterol balance and preventing atherosclerosis. Activating these enzymes with certain drugs and compounds can help eliminate excess cholesterol, reduce arterial plaque, and lower the risk of coronary heart disease.

Area of Science:

  • Biochemistry and Molecular Biology
  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Lipoproteins, including HDL-C and LDL-C, are key indicators of cardiovascular disease risk.
  • Elevated HDL-C and apo AI are associated with lower coronary heart disease (CHD) risk and increased longevity.
  • Elevated LDL-C and apo B levels signify increased risk of CHD and mortality.

Purpose of the Study:

  • To review the role of P450 enzymes and gene activation in cholesterol homeostasis.
  • To clarify their impact on the atherosclerotic vascular process, including prevention and regression.
  • To understand their role in manifestation of atherosclerotic disease, particularly CHD.

Main Methods:

  • Review of scientific literature on P450 enzymes, gene activation, and cholesterol metabolism.
  • Analysis of studies investigating the effects of P450 induction on atherosclerosis.
  • Examination of the role of nuclear receptors and their ligands in cholesterol elimination.

Main Results:

  • P450 enzymes are vital for cellular cholesterol homeostasis, responding to cholesterol overload by producing oxysterols.
  • Specific P450 enzymes (CYP7A1, CYP27A1, CYP46A1, CYP3A4) generate circulating oxysterols that activate cholesterol-eliminating genes via nuclear receptors.
  • Drugs and compounds activating nuclear receptors (e.g., LXR, PXR) induce P450 and cholesterol elimination pathways, preventing/regressing atherosclerosis and reducing cardiovascular events.

Conclusions:

  • P450 enzymes are essential for maintaining cholesterol balance and counteracting atherosclerosis.
  • Activation of P450 and related genes promotes cholesterol elimination and protects against atherosclerotic disease.
  • Pharmacological and non-pharmacological agents that induce P450 pathways can prevent/regress atherosclerosis and reduce CHD incidence.
Abstract

More Related Videos

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling09:33

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling

Published on: March 20, 2018

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...